COVID - 19

ACE2: SARS-CoV-2 Spike Compound Screening Bioassay

  • Evaluation of test compounds able to interfere with the binding of the SARS-CoV-2 Spike protein with its target, the ACE2 protein exposed on the host cell surface.
  • Identification of potential compounds that will contrast SARS-CoV-2 infection

Sequential incubation is performed in 96-well plate according to test samples as:

  1. ACE2 protein immobilisation
  2. Test compound pre-incubation
  3. SARS-CoV-2 Spike protein incubation
  4. Add anti-tag-HRP
  5. Initiate reaction with HRP substrate
  6. Detect chemiluminescence

Ideal compound candidates will contrast the binding of SARS-CoV-2 Spike with ACE2

Assay Principle

For more information on how Cellomatics Biosciences can assist you, please contact us or request a consultation.

Get a consultation today

We offer more possibilities to meet your every need.
Cellomatics Biosciences Ltd Logo
Cellomatics Biosciences Ltd. is a specialised Contract Research Organisation (CRO) providing bespoke preclinical laboratory based services.

Contact Details